The TIPP opioid peptide family: Development of ? antagonists, ? agonists, and mixed ? agonist/? antagonists
- 1 January 1999
- journal article
- review article
- Published by Wiley in Biopolymers
- Vol. 51 (6) , 411-425
- https://doi.org/10.1002/(sici)1097-0282(1999)51:6<411::aid-bip4>3.0.co;2-z
Abstract
The discovery of the prototype δ opioid antagonists TIPP (H–Tyr–Tic–Phe–Phe–OH) and TIP (H–Tyr–Tic–Phe–OH) in 1992 was followed by extensive structure–activity relationship studies, leading to the development of analogues that are of interest as pharmacological tools or as potential therapeutic agents. Stable TIPP‐derived δ opioid antagonists with subnanomolar δ receptor binding affinity and extraordinary δ receptor selectivity include TIPP[Ψ] (H–Tyr–TicΨ[CH2NH]Phe–Phe–OH] and TICP[Ψ] (H–Tyr–TicΨ[CH2NH]Cha–Phe–OH); Cha: cyclohexylalanine), which are widely used in opioid research. Theoretical conformational analyses in conjunction with the pharmacological characterization of conformationally constrained TIPP analogues led to a definitive model of the receptor‐bound conformation of H–Tyr–Tic–(Phe–Phe)–OH‐related δ opioid antagonists, which is characterized by all‐trans peptide bonds. Further structure–activity studies revealed that the δ antagonist vs δ agonist behavior of TIP(P)‐derived compounds depended on very subtle structural differences in diverse locations of the molecule and suggested a δ receptor model involving a number of different inactive receptor conformations. A further outcome of these studies was the identification of a new class of potent and very selective dipeptide δ agonists of the general formula H–Tyr–Tic–NH–X (X = arylalkyl), which are of interest for drug development because of their low molecular weight and lipophilic character. Most interestingly, TIPP analogues containing a C‐terminal carboxamide group displayed a mixed μ agonist/δ antagonist profile, and thus were expected to be analgesics with a low propensity to produce tolerance and physical dependence. This turned out to be the case with the TIPP‐derived μ agonist/δ antagonist DIPP‐NH2[Ψ] (H–Dmt–TicΨ[CH2NH]Phe–Phe–NH2); Dmt: 2′,6′‐ dimethyltyrosine). © 2000 John Wiley & Sons, Inc. Biopoly 51: 411–425, 1999Keywords
This publication has 54 references indexed in Scilit:
- Cocaine self-administration and naltrindole, a delta-selective opioid antagonistNeuroReport, 1995
- Opioid-induced stimulation of fetal respiratory activity by [D-Ala2]deltorphin IEuropean Journal of Pharmacology, 1993
- Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists.Proceedings of the National Academy of Sciences, 1992
- THE IMMUNOSUPPRESSIVE EFFECT OF δ-OPIOID RECEPTOR ANTAGONIST ON RAT RENAL ALLOGRAFT SURVIVALTransplantation, 1992
- Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins.Proceedings of the National Academy of Sciences, 1989
- Recent developments in the design of receptor specific opioid peptidesMedicinal Research Reviews, 1989
- Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonistEuropean Journal of Pharmacology, 1988
- Selectivities of opioid peptide analogues as agonists and antagonists at the δ‐receptorBritish Journal of Pharmacology, 1984
- ICI 174864: A highly selective antagonist for the opioid Δ-receptorEuropean Journal of Pharmacology, 1984
- Selectivity of minimum structure enkephalinsLife Sciences, 1982